Skip to main content
Equibles
VRCA logo

VRCA · Verrica Pharmaceuticals Inc. · Earnings Call Transcripts & Audio

Track VRCA — free

Use VRCA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRCA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.80 +0.34 (+7.51%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$75.07M
Shares
17.18M
Volume · Sep 30 50.99K Avg daily vol (3M) 62.01K

Verrica Pharmaceuticals Inc. Earnings Call Transcripts

Quarterly earnings calls for Verrica Pharmaceuticals Inc. (VRCA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼64.9% $2.92M −$24.80M '23 Q3 23-11-09 ▲2823.5% $1.99M −$24.61M '23 Q4 24-02-29 ▲10240.5% $3.83M −$20.33M '24 Q1 24-05-13 ▲2744.5% $5.18M −$17.19M '24 Q2 24-08-14 ▼82.7% $344,000 −$16.20M '24 Q4 25-03-11 ▼10.1% $3.44M −$9.74M '25 Q1 25-05-13 ▲145.4% $12.70M $204,000 '25 Q2 25-08-12 · $14.34M −$274,000 '25 Q3 25-11-14 ▲1380.2% $5.09M −$8.07M '25 Q4 26-03-11 ▲46.1% $5.02M −$9.68M '26 Q1 26-05-12 LATEST ▼53.8% $5.86M −$13.15M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
Confident tone Common warts (COVID) Phase 3 program International partnerships and launches Pipeline asset VP315 in basal cell carcinoma
Revenue
$5.86M
▼ 53.8% YoY
Diluted EPS
$-0.62
▼ 3200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Confident tone VP315 basal cell carcinoma program Ycanth commercial momentum Common warts Phase III (COV-2 / COV-3)
Revenue
$5.02M
▲ 46.1% YoY
Diluted EPS
$-0.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-11
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call
Revenue
$5.09M*
▲ 1380.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
Positive tone VP-315 basal cell carcinoma Phase III YCANTH commercial growth and dispensed units Global Phase III common warts with Torii
Revenue
$14.34M
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript
Confident tone YCANTH commercial growth Pipeline expansion Torii partnership and amended agreement
Revenue
$12.70M
▲ 145.4% YoY
Diluted EPS
$0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Verrica Pharmaceuticals Inc. (VRCA) Q1 2025 Earnings Call
Revenue
$3.44M
▼ 10.1% YoY
Diluted EPS
$-1.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Verrica Pharmaceuticals Inc. (VRCA) Q4 2024 Earnings Call Transcript
Positive tone Pipeline Expansion - Common Warts and YCANTH Label Expansion BP-315 / Basal Cell Carcinoma Program Financial Position and Capital Raise
Revenue
$344,000*
▼ 82.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-14
Verrica Pharmaceuticals Inc. (VRCA) Q2 2024 Earnings Call Transcript
Confident tone YCANTH commercial launch and revenue VP-315 basal cell carcinoma Phase 2 results Distribution and GPO partnerships
Revenue
$5.18M
▲ 2744.5% YoY
Diluted EPS
$-3.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Verrica Pharmaceuticals Inc. (VRCA) Q1 2024 Earnings Call Transcript
Confident tone YCANTH commercial launch and revenue growth Regulatory milestones and exclusivity Pipeline advancement (common warts and VP-315)
Revenue
$3.83M
▲ 10240.5% YoY
Diluted EPS
$-4.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Confident tone YCANTH Commercial Launch Reimbursement and Coverage Distribution Expansion
Revenue
$1.99M*
▲ 2823.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript
Revenue
$2.92M
▼ 64.9% YoY
Diluted EPS
$-5.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-14
Verrica Pharmaceuticals Inc. (VRCA) Q2 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1660334 CUSIP 92511W207 13F (30d) 1 filings 1 filers Visit website Investor relations